Stephen Gardner to Humans
This is a "connection" page, showing publications Stephen Gardner has written about Humans.
Connection Strength
0.096
-
A double-blind, randomized, placebo-controlled study to assess the safety, antiviral activity and pharmacokinetics of GSK2336805 when given as monotherapy and in combination with peginterferon alfa-2a and ribavirin in hepatitis C virus genotype 1-infected treatment-naive subjects. Liver Int. 2014 Jul; 34(6):e89-95.
Score: 0.018
-
Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol. 2008 May; 48(5):728-35.
Score: 0.012
-
Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J Hepatol. 2005 Feb; 42(2):173-9.
Score: 0.010
-
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology. 2002 Jul; 36(1):186-94.
Score: 0.008
-
Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy. Am J Physiol Gastrointest Liver Physiol. 2016 12 01; 311(6):G1009-G1017.
Score: 0.005
-
Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int. 2015 Feb; 35(2):429-37.
Score: 0.005
-
Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014 Dec; 12(12):2113-20.e1-3.
Score: 0.005
-
Pharmacokinetic properties of single-dose lamivudine/adefovir dipivoxil fixed-dose combination in healthy Chinese male volunteers. Clin Ther. 2013 Jan; 35(1):68-76.
Score: 0.004
-
Pleiotropy and allelic heterogeneity in the TOMM40-APOE genomic region related to clinical and metabolic features of hepatitis C infection. Hum Genet. 2012 Dec; 131(12):1911-20.
Score: 0.004
-
Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C. J Hepatol. 2011 Dec; 55(6):1195-200.
Score: 0.004
-
Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010 Jun; 51(6):1904-11.
Score: 0.003
-
Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. 2010 Apr; 138(4):1365-73, 1373.e1-2.
Score: 0.003
-
Predictors of virologic response to Lamivudine treatment in children with chronic hepatitis B infection. Pediatr Infect Dis J. 2004 May; 23(5):441-5.
Score: 0.002
-
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology. 2004 Jan; 126(1):81-90.
Score: 0.002
-
Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003 Dec; 125(6):1714-22.
Score: 0.002
-
Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 2003 Apr; 37(4):748-55.
Score: 0.002
-
Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003 Jan; 124(1):105-17.
Score: 0.002
-
A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis. Liver Transpl. 2003 Jan; 9(1):49-56.
Score: 0.002
-
Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med. 2002 May 30; 346(22):1706-13.
Score: 0.002